source
- Heraeus Medevio issues recall of vascular guidewires over coating safety riskThe FDA's Center for Devices and Radiological Health has posted an Early Alert warning about a potentially high‑risk issue with certain vascular guidewires. The alert notes that the coating on the…
- FDA approves Regeneron's Livsayis, first RNAi therapy for generalized myasthenia gravisThe Food and Drug Administration approved Regeneron's Livsayis, an RNA interference drug for generalized myasthenia gravis, marking the company's first marketed RNAi therapy. The drug, originally…